Boston Scientific has recently reported the results of the Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI)trial; part of the JACTAX stent program. [30] The JACTAX stent con ...
Hosted on MSN2mon
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth NowBoston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus ...
Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...
Over the past decade, drug-eluting stents (DES) have greatly transformed the field of interventional cardiology. Generally, three components are included in a DES system: a metal stent platform ...
The global cardiovascular devices market, valued at US$72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback